Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboxymethylcellulose sodium (carmellose sodium) is a high-molecular-weight, water-soluble cellulose derivative used primarily as an ophthalmic lubricant. It is a mucoadhesive polymer that increases the viscosity of the tear film and prolongs the retention time of the solution on the ocular surface. By binding to corneal epithelial cells, it provides a protective barrier and promotes surface hydration, offering temporary relief from burning, irritation, and discomfort associated with dry eye disease (keratoconjunctivitis sicca) or environmental exposure to wind and sun. Sanjar Pharma manufactures this agent as a generic sterile ophthalmic solution, often formulated to mimic the properties of natural tears.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carmellose sodium.